Business Description
Estrella Immunopharma Inc
NAICS : 541714
SIC : 2834
ISIN : US2975841048
Description
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -4.07 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -94.8 | |||||
3-Year EPS without NRI Growth Rate | -93.9 | |||||
3-Year FCF Growth Rate | -6.1 | |||||
3-Year Book Growth Rate | -108.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.19 | |||||
9-Day RSI | 36.71 | |||||
14-Day RSI | 38.6 | |||||
3-1 Month Momentum % | -32.63 | |||||
6-1 Month Momentum % | -36.49 | |||||
12-1 Month Momentum % | -17.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.2 | |||||
Quick Ratio | 0.2 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -25.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -330.12 | |||||
ROIC % | -605.74 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -3.19 | |||||
EV-to-EBITDA | -3.19 | |||||
EV-to-FCF | -3.33 | |||||
Earnings Yield (Greenblatt) % | -31.35 | |||||
FCF Yield % | -29.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ESLA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Estrella Immunopharma Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.24 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 146.36 | ||
| 14-Day RSI | 38.6 | ||
| 14-Day ATR ($) | 0.060426 | ||
| 20-Day SMA ($) | 0.728118 | ||
| 12-1 Month Momentum % | -17.57 | ||
| 52-Week Range ($) | 0.6781 - 3.15 | ||
| Shares Outstanding (Mil) | 43.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Estrella Immunopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Estrella Immunopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-11-12 | In 76 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-13 | 0.74 (+0.11%) | ||
| General meeting for 2025 | 2026-06-29 10:00 | 0.98 (+3.45%) | ||
| Third quarter earnings results for 2026 | 2026-05-18 | 1.11 (-9.02%) | ||
| Annual report for 2025 | 2026-03-18 | 1.11 (-7.50%) | ||
| First quarter earnings results for 2026 | 2025-11-12 | 2.51 (-0.79%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-12 | 0.87 (+5.10%) | ||
| Third quarter earnings results for 2025 | 2025-05-14 | 1.03 (-0.95%) | ||
| First quarter earnings results for 2025 | 2024-11-14 | 0.84 (+3.40%) | ||
| Third quarter earnings results for 2024 | 2024-11-14 | 0.84 (+3.40%) |
Show
Entries
Estrella Immunopharma Inc Frequently Asked Questions
What is Estrella Immunopharma Inc(ESLA)'s stock price today?
The current price of ESLA is $0.71. The 52 week high of ESLA is $3.15 and 52 week low is $0.68.
When is next earnings date of Estrella Immunopharma Inc(ESLA)?
The next earnings date of Estrella Immunopharma Inc(ESLA) is 2026-11-12 Est..
Does Estrella Immunopharma Inc(ESLA) pay dividends? If so, how much?
Estrella Immunopharma Inc(ESLA) does not pay dividend.
Press Release
Articles on Estrella Immunopharma Inc
ARMISTICE CAPITAL, LLC Reduces Stake in Estrella Immunopharma Inc (ESLA) by Nearly Half
Aug 21, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers